Dr. Inam Ullah is a cardiovascular researcher and PhD scholar in Internal Medicine (Cardiology) at The First Affiliated Hospital of Nanjing Medical University, China. His clinical and research interests span coronary artery disease, myocardial infarction, heart failure, valvular heart disease, antiplatelet therapy, chronic total occlusions, and transradial interventions. His doctoral research focuses on radial artery occlusion rates with different heparin dosing regimens. Dr. Ullah holds an MS in Cardiology from Nanjing Medical University and a BSc (Hons) in Cardiology from Khyber Medical University, Pakistan. He has gained clinical experience across leading cardiology departments including Lady Reading Hospital, Khyber Teaching Hospital, and Hayatabad Medical Complex in Peshawar. He has authored and co-authored several high-impact publications in SCIE and Scopus-indexed journals such as the Journal of the American Heart Association, European Journal of Clinical Pharmacology, British Journal of Haematology, and Free Radical Biology and Medicine. His collaborative research addresses antiplatelet therapy, pharmacogenomics, PCI optimization, and cardiac pharmacology. He is also actively engaged in systematic reviews and multicenter clinical trials. Dr. Ullah has worked on several major research projects under prestigious funding agencies in China, including the National Natural Science Foundation and Jiangsu Province’s R&D Programs. His academic achievements are supported by the Chinese Government Scholarship and numerous international certifications in cardiovascular pharmacology, medical informatics, and public health. With strong analytical, scientific writing, and biostatistical skills, Dr. Ullah continues to contribute to translational cardiovascular research and seeks to integrate clinical evidence into interventional cardiology practices.